Skip to main content
Journal cover image

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Publication ,  Journal Article
Graham, BS; Matthews, TJ; Belshe, RB; Clements, ML; Dolin, R; Wright, PF; Gorse, GJ; Schwartz, DH; Keefer, MC; Bolognesi, DP
Published in: J Infect Dis
March 1993

Twelve vaccinia-naive volunteers were inoculated with recombinant vaccinia virus expressing the human immunodeficiency virus type 1 (HIV-1) strain IIIB (HIV-1IIIB) envelope glycoprotein gp160 and subsequently immunized with 640 micrograms of recombinant (r) gp160 protein produced in baculovirus. After booster immunization with rgp160, the sera of all vaccinees showed strong antibody responses detected by Western blot and ELISA; 8 had neutralizing activity and 5 had fusion inhibition activity against the homologous strain; 5 blocked binding of CD4 cells to gp120. Cross-reactive neutralization of HIV-1MN was detected in 3 of 8 sera that neutralized HIV-1IIIB. The combination of live recombinant vaccinia followed by subunit booster immunization was more immunogenic than either product alone and represents a promising approach for HIV-1 immunoprophylaxis. Further definition of recombinant vaccinia safety and augmentation of immune responses to geographically prevalent HIV-1 strains will be necessary before expanding clinical trials to high-risk groups.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

March 1993

Volume

167

Issue

3

Start / End Page

533 / 537

Location

United States

Related Subject Headings

  • Vaccinia virus
  • Time Factors
  • Recombinant Proteins
  • Protein Precursors
  • Peptide Fragments
  • Neutralization Tests
  • Molecular Sequence Data
  • Microbiology
  • Immunization, Secondary
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Graham, B. S., Matthews, T. J., Belshe, R. B., Clements, M. L., Dolin, R., Wright, P. F., … Bolognesi, D. P. (1993). Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis, 167(3), 533–537. https://doi.org/10.1093/infdis/167.3.533
Graham, B. S., T. J. Matthews, R. B. Belshe, M. L. Clements, R. Dolin, P. F. Wright, G. J. Gorse, D. H. Schwartz, M. C. Keefer, and D. P. Bolognesi. “Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.J Infect Dis 167, no. 3 (March 1993): 533–37. https://doi.org/10.1093/infdis/167.3.533.
Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis. 1993 Mar;167(3):533–537.
Journal cover image

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

March 1993

Volume

167

Issue

3

Start / End Page

533 / 537

Location

United States

Related Subject Headings

  • Vaccinia virus
  • Time Factors
  • Recombinant Proteins
  • Protein Precursors
  • Peptide Fragments
  • Neutralization Tests
  • Molecular Sequence Data
  • Microbiology
  • Immunization, Secondary
  • Humans